Cheyenne Personal Injury Lawyer

SurgeMaster Surge Protectors Recalled By Belkin

Chrissie Cole — Tue, 27 Oct 2009 11:28:00 GMT

Belkin International, in cooperation with the CPSC, announced a voluntary recall of SurgeMaster Surge Protectors, because the molding on the rotating plug can crack or detach, posing a shock hazard.

To this date, the company has received seven consumer reports of the molding cracking. No injuries were reported.

The recalled SurgeMaster surge protectors were sold from January to December 2003. The following models are affected by the recall: F9G930-10, F9G930v10, F9G930-10-W and F9G930-10-SN.

Belkin shold be contacted for a new replacement, but in the meantime, consumers should stop using the recalled power strips.

Consumer Information: For Contact Belkin toll-free at 800-952-1465 between 9 a.m. and 5 p.m. PT Monday - Friday or visit www.belkin.com/recall

Originally posted at InjuryBoard by Chrissie Cole

Cheyenne To Pass Cell Phone Ban

Chrissie Cole — Fri, 18 Sep 2009 01:15:00 GMT

The Cheyenne City Council recently voted 7-1 to pass a ban on using cell phones while driving, with the exception of hands-free devices. But, until October 15, police will only enforce it if a cell phone is a contributing factor in a crash.

Officers are not going to stop vehicles with out-of-state plates, as its cell phone wielding driver would presumably be using the device to find his way around, said Councilman Don Pierson, the city’s former police chief.

On the other hand, local residents will be stopped, ticketed and fined," Pierson said.

According to Rick Kaysen, crews will be putting up signs at the city’s major entrances warning visitors of the ban.

An estimated 20 percent of drivers are text while behind the wheel, according to a Nationwide Insurance study last year. Among young people, between the ages of 18 to 24, that number skyrockets to 66 percent.

Originally posted at InjuryBoard by Chrissie Cole

Hydroxycut Products Recalled Due To Risk Of Liver Injury

Chrissie Cole — Fri, 01 May 2009 00:11:00 GMT

Some Hydroxycut products have been associated with serious liver injuries and as such consumers should immediately stop taking these products.

The Food and Drug Administration (FDA) has received 23 reports of liver injury, including jaundice and elevated liver enzymes. Other adverse reports include seizures, heart problems and rhabdomyolysis, another type of muscle damage.

Hydroxycut products are dietary supplements marketed for weight loss, fat burners, energy-enhancers and water loss under the Iovate and MuscleTech brands.

Below is a list of recalled Hydroxycut products:

Hydroxycut Regular Rapid Release Caplets
Hydroxycut Caffeine-Free Rapid Release Caplets
Hydroxycut Hardcore Liquid Caplets
Hydroxycut Max Liquid Caplets
Hydroxycut Regular Drink Packets
Hydroxycut Caffeine-Free Drink Packets
Hydroxycut Hardcore Drink Packets (Ignition Stix)
Hydroxycut Max Drink Packets
Hydroxycut Liquid Shots
Hydroxycut Hardcore RTDs (Ready-to-Drink)
Hydroxycut Max Aqua Shed
Hydroxycut 24
Hydroxycut Carb Control
Hydroxycut Natural

* Not included in the recall are Hydroxycut Cleanse and Hoodia.

Although rare, liver injury was reported by patients at doses of Hydroxycut recommended on the bottle. Symptoms of liver injury include jaundice and brown urine. Other symptoms can include abdominal pain, vomiting, loss of appetitie, excessive fatigue, weakness, nausea and itching.

“The FDA urges consumers to discontinue use of Hydroxycut products in order to avoid any undue risk. Adverse events are rare, but exist. Consumers should consult a physician or other health care professional if they are experiencing symptoms possibly associated with these products,” said Linda Katz, M.D., interim chief medical officer of the FDA’s Center for Food Safety and Applied Nutrition.

Liver-related disorders have not been reported in all Hydroxycut products, but the company has agreed to recall all of the products listed above.

For more information and to report any adverse events related to Hydroxycut products, please visit the FDA Web site.#

Originally posted at InjuryBoard by Chrissie Cole

Acer Recalls Desktop Computers Due To Burn Hazard

Chrissie Cole — Thu, 19 Mar 2009 12:01:00 GMT

Acer America Corp, in conjunction with CPSC, announced a voluntary recall of Acer Predator Desktop Computers because the insulation on the internal wiring can become bent or stripped causing the wires to overheat, which poses a burn hazard to users.

To date, while no injuries have been reported, the company has received two reports of the computers short circuiting resulting in melted internal components and external casing. Both incidents happened outside the U.S.

The recalled products are Acer Predator Desktop Computers with model numbers ASG7200 and ASG7700.

Consumers are advised to contact Acer to schedule a free repair and to stop using the recalled computers.

Consumer Contact: For more information, contact Acer directly at (866) 695-2237 anytime, or visit the firm’s Web site at www.acer.com

Originally posted at InjuryBoard by Chrissie Cole

Proposal Makes Regulating On the Job Toxin Exposure More Difficult

Kyle Bachus — Wed, 30 Jul 2008 04:00:00 GMT

In news that should surprise absolutely no one, political appointees at the Department of Labor, working in secrecy and over the objection of department experts, are trying to ram through a proposal in the waning days of the Bush administration which would make it harder to regulate workplace toxin exposure.

Sources told the Washington Post that the proposal, which was not disclosed in public notices as required and has not yet been made available to the public, calls for change in the way the government assesses workplace-safety regulations and “would also require the agency to take an extra step before setting new limits on chemicals in the workplace by allowing an additional round of challenges to agency risk assessments.” This extra step, George Washington University epidemiologist and professor David Michaels told the Post, “is a guarantee to keep any more worker safety regulation from ever coming out of OSHA… This is being done in secrecy, to be sprung before President Bush leaves office, to cripple the next administration."

This effort has been spearheaded by Deborah Misir, a former ethics adviser to President Bush and a deputy in the department’s policy office, who “did not consult scientific and workplace-risk-assessment experts in OSHA and the Mine Safety and Health Administration, according to sources briefed on her work.” When she did consult the experts, “they objected to the legality and substance of the proposal.”

No matter, the department simply didn’t include the proposal in its semiannual agenda, and as if by magic, the risk-assessment overhaul, which happens to benefit businesses who complain that the risk of workplace toxin exposure is overestimated, suddenly became top priority, vaulting over trifling matters like of reducing on-the-job deaths, injuries and illnesses caused by various toxins.

While it can be argued, as a consultant who worked with the department on a study of the risk-assessment process does here, that the changes in the proposal will cut down on bureaucratic red-tape and preserve jobs, the last-minute nature of the proposed regulation, after almost eight years of nearly total inaction, is suspicious, to say the least. Peg Seminario, director of health and safety policy at the AFL-CIO, related these suspicions to the Post: “They are trying to essentially change the job safety and health laws and reduce required workplace protections through a midnight regulation."

Thomas Connell

Summer Intern 2008

J.D. Candidate 2010

University of Colorado

Originally posted at InjuryBoard by Kyle Bachus

AIDS: Still deadly

Darin Schanker — Thu, 19 Jun 2008 15:41:12 GMT

Naturally, game 3 of the NBA Finals was a star-studded event. The classic rivalry between the Boston Celtics and the Los Angeles Lakers reigniting after 21 years attracted L.A. celebrities and NBA legends in equal numbers, and there, sitting court-side, looking hale and healthy, was Earvin “Magic” Johnson, quintessential Laker champion and one of the NBA’s all-time greats.

Seventeen years ago, very few would have predicted that Johnson would live to see the new millennium. The shock of Johnson’s November 7, 1991 announcement that he was HIV-positive is hard to fathom today: people like Johnson and others have successfully fought and lived with the disease for years. But from 1986 to 1996, over 300,000 people with AIDS died.

The precipitous decline in AIDS-related fatalities since the height of the epidemic, mainly due to the introduction of the antiretroviral drug cocktails (HAART or highly active antiretroviral theraphy) which have helped keep Magic health since 1996, has given rise to the myth that the disease can be treated and effectively cured. But Americans are still dying from AIDS.

The people who are most likely to die are the poor who can’t afford to get tested and treated (HAART can cost upwards of $1,000 a month), or who don’t get tested until they have full-blown AIDS; those made especially vulnerable to cancer or heart disease from their drug cocktails; and those long-term survivors whose earlier, pre-HAART treatment caused to virus to become drug-resistant. So while we should be optimistic about the future, we should keep in mind that there is no still magic cure for HIV/AIDS.

Thomas Connell

Summer Intern 2008

JD Candidate, 2010

University of Colorado

Originally posted at InjuryBoard by Darin Schanker

McKesson Corporation to pay $13.25 Million in Settlements

Linda Snyder — Tue, 06 May 2008 19:51:44 GMT

McKesson Corporation has reached an agreement to pay $13.25 million in civil and administrative settlements with the U.S. Drug Enforcement Administration and six U.S. Attorneys for failing to report sales of certain drugs to on-line pharmacies.

Did you ever wonder how illegal on-line pharmacies are able to obtain the drugs they sell to customers without a legal prescription? The answer is simple…they buy them from the drug manufacturers just like your regular corner drug store.

The problem is the drug manufacturers are violating the Controlled Substances Act by failing to report to the DEA any suspicious sales which include orders that are unusually large, unusually frequent, and/or deviated substantially from the normal pattern. By failing to report the sales to the on-line pharmacies, drug manufacturers are not only violating the Controlled Substances Act they are also contributing to the growing epidemic of prescription drug abuse.

"The abuse of prescription medications is a significant and growing problem, and there is an erroneous perception among our youth that the recreational use of these powerful medications is somehow safer than the abuse of illegal drugs such as cocaine, meth, and heroin,” said Deputy Attorney General Mark Filip. “Today's settlement makes clear that the Department of Justice is committed to doing its part to curtail illegal access to these dangerous drugs."

My question is what would motivate a drug manufacturer to report an upsurge in their sales? The money is pouring in, so why would they do anything to jeopardize this influx of revenue? The drug companies have no reason to comply until it hits them in the pocketbook and I suspect that while this $13.25 million dollar settlement stung a little, it was probably just a drop in the bucket compared to the profit they made before they got caught.

Originally posted at InjuryBoard by Linda Snyder

Vytorin and Zetia Only to be Used as Last Resort

Linda Snyder — Thu, 03 Apr 2008 13:15:52 GMT

The American College of Cardiology has recommended that the popular drugs Vytorin and Zetia should only be used after all other cholesterol lowering drugs fail. The panel's spokesman, Harlan Krumholz of Yale University, said: "Our strongest recommendation is that people need to go back to statins. … If you were put on this drug before you were fully treated on a statin, you should go back."

The panel based its findings on detailed evidence from a controversial study showing Vytorin worked no better than a statin drug currently being sold as a cheap generic.

Zetia was approved in 2002 and Vytorin in 2004 based on research showing that they dramatically reduce levels of LDL. High LDL levels can raise heart attack risk, however these drugs were not proven to actually save lives. Both Zetia and Vytorin are made up of a drug, ezetimibe, which blocks the absorption of bad cholesterol, LDL, in the gut. Vytorin also contains the cholesterol-lowering drug simvastatin. Statins work by blocking LDL synthesis in the liver.

The two-year trial, sponsored by the drugmakers Merck and Schering-Plough, involved 720 patients who had a severe form of inherited high cholesterol. Half were given simvastatin, also sold as Zocor, and a placebo. The rest were treated with the combo sold as Vytorin.

The drugs' performance was evaluated by measuring fatty deposits in the carotid arteries that supply the brain and femoral arteries in the legs. Researchers found no differences between patients who took simvastatin alone and those who took Vytorin.

"There is absolutely no difference … between the two treatment groups," said lead investigator John Kastelein of the Academic Medical Center in Amsterdam at the group's annual scientific session.

What makes this study particularly interesting is, in a second study published in the New England Journal, Krumholz and his co-workers scrutinzed prescribing practices in the US, where a $200-million-a-year consumer advertising campaign helped build Vytorin and Zetia into best-sellers. This marketing effort helped drug makers Merck and Schering-Plough gain a 15 percent market share for cholesterol lowing drugs in the US. In Canada, where direct-to-consumer advertising is banned, the market share was 3 percent.

Furthermore, earlier studies have shown that pharmaceutical companies spend almost twice as much on marketing a drug than they spend on research and development for that same product.

So, the question is…did the drug companies know about or suspect the effectiveness of Vytorin and Zetia before they put these drugs on the market, knowing they could make a large profit before the truth caught up with them? Did they choose to put profit over consumer safety by spending more money on the marketing campaigns instead of research and development?

Appropriately enough, shares of Merck (MRK) and Schering-Plough (SGP), the companies that market Vytorin, plunged this week to their lowest levels in years.

Originally posted at InjuryBoard by Linda Snyder

Dennis Quaid Sues Baxter for Heparin Overdose

Linda Snyder — Tue, 18 Mar 2008 15:07:11 GMT

Actor Dennis Quaid and his wife Kimberly Buffington filed a lawsuit in December 2007 against Baxter Healthcare Corporation, claiming the drug maker was negligent when packaging different doses of the same drug in similar packaging. Both heparin and the lower dose version, hep-lock are packaged in similar vials with blue backgrounds and very small print on both labels.

Quaid's newborn twins, who were hospitalized for staph infections, were both administered multiple near fatal dose of the blood thinner Heparin at Cedars-Sinai Medical Center in Los Angeles last November. Zoe Grace and Thomas Boone were given 10,000 units of Heparin, rather than the 10 units they were prescribed. Babies typically get Heparin in their IV catheters to prevent clotting because their IV lines are so tiny. It's necessary for the babies to survive.

In 2006, a similar incident in Indiana involving 6 newborns which resulted in the death of 3 babies, motivated Baxter to redesign the packaging and issue a warning to hospitals. There were also at least two other incidents in 2001 involving infants, both of which recovered. What Baxter didn't do was recall the old stock that was sitting in hospitals all over the country, including Cedars-Sinai in Los Angeles

Quaid and his wife are in the process creating a foundation to fight the epidemic of hospital errors. Quaid told 60 Minutes, he hoped that Cedars-Sinai would also take a lead in fighting hospital errors.

In an interview with "60 Minutes," Baxter executive Debra Bello explained in an interview with "60 Minutes", "the product was safe and effective, and the errors were preventable and due to failures in their system,"

The argument could be made that it's not Baxter's fault because they changed the labeling. The argument could be made that it's not the nurse's fault because the packaging was so similar, you couldn't tell the difference. The argument could be made that it's not the pharmacy's fault because they couldn't tell the difference between the adult dosage and the infant dosage because the print on the label was so small . The argument could be made that mistakes happen. The argument could be made that Pharmaceutical Companies and hospitals won't take steps to correct those mistakes until someone files a lawsuit and it hurts them in their pocketbooks.

Originally posted at InjuryBoard by Linda Snyder

A Friend in Need of a Kidney Transplant

Linda Snyder — Mon, 25 Feb 2008 17:02:38 GMT

Imagine the hope and excitement of graduating from high school and looking forward to the next chapter of your life as you head for college to pursue career of your dreams.

Imagine the devastation as you learn you have a serious disorder that will put those dreams on hold and in fact threatens your very life.

This is Kelsey Crider's reality. A bright, articulate young woman, Kelsey Crider's future looked promising as she was headed for Ft. Lewis College in Durango, Colorado. Two weeks after her high school graduation, Kelsey had routine blood work done. Initial tests came back indicating she was anemic and her hematocrit was low. Further tests revealed that Kelsey had Medullary Cystic Kidney Disease, a hereditary disorder in which cysts develop deep within both kidneys. With no prior symptons her kidneys gradually lost their ability to function. At this point, Kelsey's kidney was only functioning at 12% and she was suffering from kidney failure and needed an immediate kidney transplant.

Fortunately, Kelsey's father was a match and the transplant went without a hitch. Unfortunately, even after a dramatic battle and a lengthy hospital stay, Kelsey's body rejected her new kidney and is now on dialysis 3 days a week at four hours each session. Throughout her ordeal Kelsey has persevered with positive attitude and a smile on her face.

Her dream of attending college to become a photographer has been put on hold as Kelsey focuses on recovering from her surgeries and massive doses of anti-rejection medication. Her doctor has advised that her body needs to rest and heal before they attempt another surgery. In the meantime, we want to find her another donor.

Whether you consider becoming a living kidney donor or can pass this story on to your contacts, let's do what we can help this family and give this young lady a chance to reach her dreams.

To learn more, please contact Steve Crider at rockymtngatr@yahoo.com or call 303.530.2929.

Originally posted at InjuryBoard by Linda Snyder